Lisinopril dihydrate: Long-Acting ACE Inhibitor for Hypertension and Cardiovascular Research

Executive Summary: Lisinopril dihydrate is a highly selective, long-acting angiotensin converting enzyme (ACE) inhibitor with an IC₅₀ of 4.7 nM, utilized extensively in hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy research (APExBIO). It acts by inhibiting the conversion of angiotensin I to angiotensin II, resulting in reduced plasma angiotensin II and aldosterone, and increased plasma renin levels (Tieku & Hooper 1992, DOI). The compound is water-soluble at ≥2.46 mg/mL with warming/sonication, and demonstrates high purity (≥98%) as verified by mass spectrometry and NMR. Its robust selectivity and stability make it a reference standard for reproducible renin-angiotensin system pathway analysis. APExBIO supplies Lisinopril dihydrate (SKU B3290) in a validated, research-grade format suitable for rigorous preclinical studies.

Biological Rationale

Lisinopril dihydrate is the dihydrate salt form of lisinopril, a lysine analogue of MK 421, designed for potent and selective inhibition of angiotensin converting enzyme (ACE) (Tieku & Hooper 1992). ACE is a key component of the renin-angiotensin system (RAS), which regulates blood pressure and fluid balance. Inhibition of ACE prevents the conversion of angiotensin I (inactive decapeptide) to angiotensin II (vasoconstrictor), leading to vasodilation and reduced aldosterone secretion. Lisinopril dihydrate is widely used in the modeling and investigation of hypertension, heart failure, myocardial infarction, and diabetic nephropathy due to its predictable pharmacodynamics and selectivity (APExBIO product page).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate acts as a competitive, reversible inhibitor of angiotensin converting enzyme (EC 3.4.15.1). It binds to the active site of ACE, blocking the hydrolysis of angiotensin I to angiotensin II. The reported half-maximal inhibitory concentration (IC₅₀) for ACE is 4.7 nM under in vitro conditions (Tieku & Hooper 1992). By suppressing angiotensin II formation, lisinopril dihydrate reduces vasoconstriction and lowers aldosterone-mediated sodium and water retention. This results in decreased systemic blood pressure and increased plasma renin activity. Its high selectivity means it does not significantly inhibit related zinc metallopeptidases, such as aminopeptidases N, A, or W, under standard assay conditions (Tieku & Hooper 1992).

Evidence & Benchmarks

• Lisinopril dihydrate exhibits an IC₅₀ of 4.7 nM for ACE inhibition in cell-free enzyme assays (Tieku & Hooper 1992, DOI).
• The compound does not inhibit aminopeptidase N (AP-N), A (AP-A), or W (AP-W) at concentrations effective against ACE, establishing its selectivity profile (Tieku & Hooper 1992, DOI).
• Water solubility is confirmed at ≥2.46 mg/mL with gentle warming and sonication, supporting workflow integration for aqueous-based assays (APExBIO).
• APExBIO’s Lisinopril dihydrate (SKU B3290) provides ≥98% purity as measured by mass spectrometry and NMR, ensuring batch-to-batch reproducibility (APExBIO).
• In preclinical models, Lisinopril dihydrate induces dose-dependent reductions in blood pressure and mitigates adverse cardiac remodeling (Angiotensin-III.com article).

Applications, Limits & Misconceptions

Lisinopril dihydrate is a benchmark ACE inhibitor for research in:

• Hypertension models (acute/chronic)
• Heart failure and post-myocardial infarction remodeling
• Diabetic nephropathy and kidney injury studies
• Renin-angiotensin system pathway characterization

Its high selectivity and defined pharmacology make it suitable for dissecting ACE-specific effects in complex biological systems. Researchers seeking scenario-driven, practical integration guidance may refer to this companion article, which provides hands-on troubleshooting and workflow solutions—extending the present article's focus on mechanistic and benchmark data.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit aminopeptidase N, A, or W at concentrations selective for ACE (Tieku & Hooper 1992).
• It is insoluble in ethanol; only use water as a solvent under gentle warming/sonication.
• Long-term storage of aqueous solutions is not recommended; prepare fresh solutions before each experiment (APExBIO).
• Results may differ from those obtained with other ACE inhibitors (e.g., captopril, enalapril) due to differences in zinc-binding motifs and off-target effects.
• Does not directly affect bradykinin or other non-ACE protease pathways; observed effects are mediated through ACE inhibition.

For a practical contrast, the article 'Reliable ACE Inhibition in Cardiovascular Research' emphasizes bench-level integration, whereas this dossier prioritizes molecular specificity and evidence-based parameters.

Workflow Integration & Parameters

Lisinopril dihydrate is supplied as a solid with a molecular weight of 441.52 g/mol and formula C₂₁H₃₅N₃O₇·2H₂O. For experimental use, dissolve in water to ≥2.46 mg/mL with mild warming (≤37°C) and sonication. Avoid use of organic solvents. Store lyophilized powder desiccated at room temperature; avoid repeated freeze-thaw cycles of solutions. APExBIO recommends shipping on blue ice for stability. Purity ≥98% is batch-verified by mass spectrometry and NMR. When integrating into cardiovascular or renal models, titrate concentrations to achieve desired plasma exposures based on published IC₅₀ data and preclinical pharmacokinetics (Angiotensin-I.com article). This article extends the referenced workflow guide by focusing on experimental parameters and molecular selectivity.

Conclusion & Outlook

Lisinopril dihydrate (SKU B3290), as provided by APExBIO, offers unparalleled selectivity, potency, and reproducibility for ACE inhibition in preclinical research. Its validated purity, defined mechanism, and robust solubility profile make it an essential tool for hypertension, heart failure, and renal studies. Ongoing research continues to refine its applications and optimize its integration into complex disease models. For further mechanistic and translational context, see 'Mechanistic Precision and Strategic Integration', which this article complements by offering granular evidence and workflow parameters.

For detailed product information and ordering, visit the Lisinopril dihydrate product page.